Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis

Abstract

Background: The role of tumour infiltrating lymphocytes (TILs) as a biomarker in non-invasive breast cancer is unclear. This meta-analysis assessed the prognostic impact of TIL levels in patients with noninvasive breast cancer. Methods: Systematic literature search was performed to identify studies assessing local recurrence in patients with non-invasive breast cancer according to TIL levels (high vs. low). Subgroup analyses per local recurrence (invasive and non-invasive) were performed. Secondary objectives were the association between TIL levels and non-invasive breast cancer subtypes, age, grade and necrosis. Odds ratios (ORs) and 95% confidence intervals (CI) were extracted from each study and a pooled analysis was conducted with random-effect model. Results: Seven studies (N ¼ 3437) were included in the present meta-analysis. High-TILs were associated with a higher likelihood of local recurrence (invasive or non-invasive, N ¼ 2941; OR 2.05; 95%CI, 1.03 e4.08; p ¼ 0.042), although with a lower likelihood of invasive local recurrence (N ¼ 1722; OR 0.69; 95% CI, 0.49e0.99; p ¼ 0.042). High-TIL levels were associated with triple-negative (OR 3.84; 95%CI, 2.23 e6.61; p < 0.001) and HER2-positive (OR 6.27; 95%CI, 4.93e7.97; p < 0.001) subtypes, high grade (OR 5.15; 95%CI, 3.69e7.19; p < 0.001) and necrosis (OR 3.09; 95%CI, 2.33e4.10; p < 0.001). Conclusions: High-TIL levels were associated with more aggressive tumours, a higher likelihood of local recurrence (invasive or non-invasive) but a lower likelihood of invasive local recurrence in patients with non-invasive breast cancer.

The prognostic value of tumor-infiltrating lymphocytes in non-small cell lung cancer patients who received neoadjuvant chemotherapy followed by surgery

“…Indeed, the correlation between TIL levels and prognosis has been demonstrated in various cancers. [8][9][10][11] A large-scale study conducted by Feng et al showed that TIL+ patients had better postoperative survival results compared with TIL-patients with pathological stage IIIA (N2) NSCLC who underwent complete cancer resection (5-year OS of 35.6% compared to 34%). 17 However, there are few reports on the relationship between TILs and the prognosis of patients with NSCLC after neoadjuvant chemotherapy.…”

“…Such responses are related to survival rate and response to treatment in patients with a variety of solid tumors, and have an impact on the overall survival (OS) and disease-free survival (DFS) of these patients. [8][9][10][11] Recent studies have demonstrated that patients with NSCLC who underwent early surgery had high levels of TILs in tumors, which were associated with an improvement in relapse-free survival rate and a decreased risk of systemic recurrence. 8 Additionally, Gataa et al reported an association between TILs and the prognosis of patients with advanced NSCLC who were receiving immunotherapy.…”

A Comprehensive Review on Electrochemical Nano Biosensors for Precise Detection of Blood-Based Oncomarkers in Breast Cancer

“…The distinction between LCIS (or lobular neoplasia) and DCIS is that LCIS refers to lobular cancer, whereas DCIS refers to milk duct cancer. Stage 0 BC includes noninvasive BC, DCIS, and LCIS [ 36 ].…”

Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast

“…Immune cells can be particularly noticeable surrounding the ducts of many DCIS, enriched in DCIS of high grade, larger size and microinvasion as well as associated with HER2+, ER– and TP53 mutation 60 . High numbers of lymphocytes have also variably been correlated with outcome, an association confounded by the use of different cut‐points and methods for assessment 61–68 . A recent meta‐analysis suggests that the method used to estimate lymphocytes is a significant cause of differences and affects prognostic impact.…”